Patents Represented by Attorney, Agent or Law Firm Nickki L. Parlet
-
Patent number: 8227420Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).Type: GrantFiled: March 9, 2010Date of Patent: July 24, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Patent number: 8148332Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: GrantFiled: July 27, 2011Date of Patent: April 3, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Patent number: 7915395Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.Type: GrantFiled: October 29, 2002Date of Patent: March 29, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
-
Patent number: 7915222Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.Type: GrantFiled: May 1, 2009Date of Patent: March 29, 2011Assignee: Bristol-Myers Squibb CompanyInventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
-
Patent number: 7829534Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.Type: GrantFiled: October 29, 2007Date of Patent: November 9, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
-
Patent number: 7705134Abstract: The present invention provides novel polynucleotides encoding BGS-4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: September 10, 2008Date of Patent: April 27, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Shujian Wu, Stanley R. Krystek, Jr., Liana M. Lee, John N. Feder, Janet D. Cheng
-
Patent number: 7700556Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: GrantFiled: March 20, 2007Date of Patent: April 20, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Patent number: 7678887Abstract: The present invention describes a newly discovered polynucleotide encoding a protein involved in the cell signaling cascade, called RET16, cloned, isolated and identified from TNF-alpha stimulated human microvascular endothelial cells, as well as mouse and rat RET16 orthologs thereof. Also described are the RET16 polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Methods for screening for modulators, particularly inhibitors, of the human RET16 protein, and use of the RET16 polynucleotide and polypeptide for therapeutics and diagnostics are described.Type: GrantFiled: February 13, 2007Date of Patent: March 16, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Charles G. Todderud, Joshua N. Finger, Jill Rillema
-
Patent number: 7671022Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.Type: GrantFiled: August 14, 2007Date of Patent: March 2, 2010Assignee: Bristol-Myers Squibb CompanyInventor: James Rusnak
-
Patent number: 7670785Abstract: The present invention is directed to polynucleotides encoding polypeptides associated with the development of rheumatoid arthritis and homologs thereof. The invention further relates to diagnostic and therapeutic methods for utilizing these polynucleotides and polypeptides in the diagnosis, treatment, and/or prevention of rheumatoid arthritis and related disease states. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, and compounds identified thereby.Type: GrantFiled: June 7, 2007Date of Patent: March 2, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Julie Carman, Steven G. Nadler, Michael A. Bowen, Michael G. Neubauer, Pin Lu
-
Patent number: 7572772Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: GrantFiled: March 19, 2007Date of Patent: August 11, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace
-
Patent number: 7541164Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. Throughout their duration, the culturing processes of the invention involving two or more downward shifts in temperature sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein. In another aspect, the methods comprise the delayed addition of polyanionic compound during the culturing period.Type: GrantFiled: December 18, 2003Date of Patent: June 2, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Bernhard M. Schilling, Linda Matlock, Stephen G. Zegarelli, William V. Burnett, Christoph E. Joosten, Jonathan D. Basch, Sivakesava Sakhamuri, Steven S. Lee
-
Patent number: 7528111Abstract: The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.Type: GrantFiled: May 8, 2007Date of Patent: May 5, 2009Assignee: Bristol-Myers Squibb CompanyInventors: George Vratsanos, Francisco Leon, Lee K. Tay, Kenneth M. Bahrt
-
Patent number: 7510844Abstract: The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies.Type: GrantFiled: January 22, 2007Date of Patent: March 31, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert M. Townsend, Catherine A. Fleener, Francisco Leon
-
Patent number: 7482327Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.Type: GrantFiled: April 6, 2006Date of Patent: January 27, 2009Assignee: Bristol-Myers Squibb CompanyInventors: David Hagerty, James Rusnak
-
Patent number: 7456256Abstract: The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: March 21, 2007Date of Patent: November 25, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Shujian Wu, Stanley R. Krystek, Jr., Liana M. Lee, John N. Feder, Janet D. Cheng
-
Patent number: 7439230Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: GrantFiled: November 3, 2004Date of Patent: October 21, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
-
Patent number: 7416876Abstract: This invention relates to isolated or recombinant N-CBZ-deprotecting enzyme polypeptides that catalyze the removal of CBZ from CBZ-protected amino acids and alcohols, and variants, modifications, and fragments thereof. Also related are isolated nucleic acids encoding N-CBZ-deprotecting enzyme polypeptides, and variants, modifications, and fragments thereof, as well as vectors and host cells comprising these nucleic acids. The invention also relates to methods of obtaining isolated nucleic acids, polypeptides, and antibodies, and methods of using polypeptides in various reactions for industrial or pharmaceutical applications.Type: GrantFiled: August 10, 2006Date of Patent: August 26, 2008Assignee: Bristol-Meyers Squibb CompanyInventors: Venkata B. Nanduri, Ramesh N. Patel, Steven L. Goldberg, Robert M. Johnston
-
Patent number: 7332303Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after innoculation.Type: GrantFiled: December 18, 2003Date of Patent: February 19, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Bernhard M. Schilling, Scott Gangloff, Dharti Kothari, Kirk Leister, Linda Matlock, Stephen G. Zegarelli, Christoph E. Joosten, Jonathan D. Basch, Sivakesava Sakhamuri, Steven S. Lee
-
Patent number: 7307064Abstract: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.Type: GrantFiled: August 3, 2004Date of Patent: December 11, 2007Assignee: Bristol-Myers Squibb CompanyInventor: James Rusnak